| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.46M | 7.68M | 6.70M | 9.69M | 7.31M | 10.53M |
| Gross Profit | 6.75M | 7.14M | 6.06M | 8.99M | 6.65M | 9.47M |
| EBITDA | -9.28M | -14.39M | -36.69M | -39.13M | -32.47M | -33.27M |
| Net Income | -17.52M | -13.51M | -36.48M | -29.61M | -37.59M | -34.33M |
Balance Sheet | ||||||
| Total Assets | 10.36M | 14.92M | 23.11M | 26.54M | 42.19M | 41.32M |
| Cash, Cash Equivalents and Short-Term Investments | 6.08M | 9.73M | 18.25M | 19.11M | 27.76M | 21.04M |
| Total Debt | 749.00K | 889.00K | 795.00K | 539.00K | 1.82M | 2.89M |
| Total Liabilities | 4.94M | 5.35M | 6.50M | 8.64M | 7.76M | 12.12M |
| Stockholders Equity | 5.42M | 9.57M | 16.61M | 16.56M | 34.42M | 29.19M |
Cash Flow | ||||||
| Free Cash Flow | -8.98M | -14.88M | -30.67M | -27.70M | -34.00M | -24.23M |
| Operating Cash Flow | -8.86M | -14.77M | -30.60M | -27.50M | -28.23M | -18.71M |
| Investing Cash Flow | -121.76K | -107.00K | -43.00K | -158.00K | -5.76M | -5.51M |
| Financing Cash Flow | 6.13M | 6.44M | 29.10M | 19.48M | 40.79M | 21.82M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | £125.52M | 33.11 | 12.39% | 0.71% | 12.10% | 27.35% | |
| ― | £155.61M | 140.65 | 11.82% | ― | 13.76% | 31.36% | |
| ― | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
| ― | £41.82M | 250.00 | ― | ― | 1.73% | -68.87% | |
| ― | £23.63M | ― | -268.88% | ― | 1.65% | 29.02% | |
| ― | £48.14M | -6.51 | -16.92% | ― | -1.09% | -6.65% | |
| ― | £10.04M | ― | ― | ― | -5.21% | 76.14% |
Cirata plc has reported a significant transformation in its operations, highlighted by the divestment of its DevOps business and a strategic focus on its Data Integration (DI) product line. The company announced a substantial 3-year contract with a leading US insurer, marking the largest direct contract in its history, and launched the Cirata Symphony platform to enhance its market positioning. Financially, Cirata has reduced its cost base significantly and improved its cash burn rate, setting a solid foundation for future growth and operational leverage. The company remains optimistic about its Q4FY25 performance, driven by early momentum and a streamlined cost structure.
The most recent analyst rating on (GB:CRTA) stock is a Hold with a £21.50 price target. To see the full list of analyst forecasts on Wandisco stock, see the GB:CRTA Stock Forecast page.
Cirata plc has secured a $3.1 million, three-year data integration contract with a leading US insurer, marking the largest direct contract in the company’s history. This contract signifies a strategic shift from a one-year legacy agreement to a longer-term partnership, enhancing Cirata’s industry positioning and potentially impacting its operations and stakeholder relationships positively.
The most recent analyst rating on (GB:CRTA) stock is a Hold with a £21.00 price target. To see the full list of analyst forecasts on Wandisco stock, see the GB:CRTA Stock Forecast page.
Cirata plc has announced a grant of share options to its CEO, Stephen Kelly, as part of its Share Options Plan. The awards, approved by the company’s Remuneration Committee, aim to align leadership incentives with shareholder interests. The awards consist of 50% share options and 50% performance-based share options, with a total of 2,400,000 options granted. This move replaces a prior award and reflects Cirata’s commitment to long-term incentives for its leadership team.
The most recent analyst rating on (GB:CRTA) stock is a Hold with a £19.50 price target. To see the full list of analyst forecasts on Wandisco stock, see the GB:CRTA Stock Forecast page.
Cirata’s recent earnings call paints a picture of robust growth tempered by execution challenges. The company reported strong revenue and bookings growth, effective cost management, and strategic partnerships. However, challenges in sales execution and customer acquisition were also highlighted, indicating areas needing improvement.
Cirata has launched ‘Cirata Symphony’, a data orchestration platform designed to simplify, secure, and accelerate enterprise data management, addressing the challenges of data silos and AI project failures. This platform enables real-time data orchestration across hybrid and multi-cloud environments, eliminating issues like vendor lock-in and latency, and positioning Cirata to capitalize on the growing market for data, AI solutions, and advanced analytics.
The most recent analyst rating on (GB:CRTA) stock is a Hold with a £19.50 price target. To see the full list of analyst forecasts on Wandisco stock, see the GB:CRTA Stock Forecast page.
Cirata plc, a company listed on the London Stock Exchange, has announced its interim unaudited results for the first half of 2025. The company reported a significant increase in revenue and bookings, with a notable shift in focus towards its Data Integration (DI) business following the divestiture of its DevOps assets. The divestiture, completed in August 2025, is part of Cirata’s strategy to concentrate on the growth potential of its DI business, which has shown substantial year-over-year growth. The company has also taken steps to reduce its cash overheads and appointed a new Chief Revenue Officer to strengthen its market presence. These strategic moves are expected to enhance Cirata’s operational efficiency and support its long-term growth objectives.
The most recent analyst rating on (GB:CRTA) stock is a Hold with a £19.50 price target. To see the full list of analyst forecasts on Wandisco stock, see the GB:CRTA Stock Forecast page.
Cirata plc has completed the divestment of its DevOps assets to BlueOptima Ltd, receiving an initial $2.5 million with a potential additional $1 million contingent on customer transfers. This move allows Cirata to concentrate on its core Data Integration business, which is pivotal for its growth strategy.
The most recent analyst rating on (GB:CRTA) stock is a Buy with a £93.00 price target. To see the full list of analyst forecasts on Wandisco stock, see the GB:CRTA Stock Forecast page.